Intra-Cellular Therapies (ITCI) PT Raised to $59 at Needham & Company; Sees >$800M in Caplyta Sales by 2026
Tweet Send to a Friend
Needham & Company analyst Ami Fadia raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $59.00 (from $55.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
